Key Details
Price
$25.75Last Dividend
$0.21Annual Revenue
$2.35 BAnnual EPS
$2.53Annual ROE
11.57%Beta
0.19Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 15, 2024Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The main stock indexes continue to rise, but there are still some lesser-known stocks that are worth considering. Some of these overlooked companies provide good dividend yields and consistent growth in their payouts, even if their stock prices don't reflect this.
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) has announced its participation in several investor conferences scheduled for December.
On November 14, 2024, Royalty Pharma plc (Nasdaq: RPRX) announced the first-ever Royalty Pharma Prize for Impact in Healthcare, which recognizes people or groups making a positive difference in healthcare. Micheal Milken received this award, which comes with a $250,000 donation to help fund medical research or educational projects related to his work.
Royalty Pharma's third-quarter results were in line with expectations, and they have slightly raised their outlook for 2024 due to good performance from their portfolio and new royalty deals. The CF franchise continues to generate significant revenue, although Vertex's Venza triple development may present some challenges. With an attractive valuation, a $1 billion buyback plan, and a promising pipeline, Royalty Pharma is considered a strong investment.
The main figures for Royalty Pharma (RPRX) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to compare these important metrics with Wall Street predictions and the results from the same period last year.
Royalty Pharma (RPRX) reported quarterly earnings of $1.04 per share, which is higher than the Zacks Consensus Estimate of $0.95 per share. This is an increase compared to earnings of $0.79 per share from the same period last year.
Royalty Pharma plc (NASDAQ:RPRX) will hold its Q3 2024 Earnings Conference Call on November 6, 2024, at 8:30 AM ET. The call will feature company leaders, including George Grofik, Pablo Legorreta, and Marshall Urist, along with participants from various financial institutions. The operator will welcome everyone to the call and thank them for their patience.
In addition to looking at analysts' predictions for Royalty Pharma's (RPRX) revenue and profits, it's important to assess forecasts for some of its main metrics. This will help us understand how the company may have done in the quarter that ended in September 2024.
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) has announced that it will release its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, before the U.S. markets open. The company will also hold a conference call and a live webcast at 8:30 a.m. Eastern Time on that day.
Royalty Pharma (RPRX) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
FAQ
- What is the primary business of Royalty Pharma?
- What is the ticker symbol for Royalty Pharma?
- Does Royalty Pharma pay dividends?
- What sector is Royalty Pharma in?
- What industry is Royalty Pharma in?
- What country is Royalty Pharma based in?
- When did Royalty Pharma go public?
- Is Royalty Pharma in the S&P 500?
- Is Royalty Pharma in the NASDAQ 100?
- Is Royalty Pharma in the Dow Jones?
- When was Royalty Pharma's last earnings report?
- When does Royalty Pharma report earnings?
- Should I buy Royalty Pharma stock now?